Biotechnology News and Research

RSS

First Edition: October 11, 2011

Today's headlines include reports about how Mitt Romney taking heat from the other GOP hopefuls, with some of the fire focusing on his Massachusetts health overhaul.

11 Oct 2011

Roche NimbleGen launches pre-capture multiplex target enrichment protocol

With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing. To enable researchers to more readily match targeted sequencing sample preparation throughput to the ever increasing throughput of next-generation sequencing, Roche NimbleGen announces the imminent launch of a pre-capture multiplex target enrichment protocol.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

New information about effects of aging on the brain

Research by biologists at the University of York and Hull York Medical School has revealed important new information about the way the brain is affected by age.

11 Oct 2011

Awards showcase Australia’s promising future in bio-sciences

The six state winners of the AusBiotech/GSK Student Excellence Awards, announced today, will next week compete for the national biosciences research award at AusBiotech 2011.

10 Oct 2011

Unither Virology receives NIAID contract for glycobiology antiviral platform

United Therapeutics Corporation announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.

10 Oct 2011

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions.

10 Oct 2011

Implementing electronic prescribing in primary care practices

Primary care physicians provide essential health services to patients of all ages and while a family physician's office is a warm, comfortable environment, a physician's practice also is a business.

7 Oct 2011

NCKU research team discovers potential target to treat osteoporosis

A National Cheng Kung University (NCKU) research team has discovered that a protein called interleukin (IL)-20 is a key to treating osteoporosis, a disease that lowers a person's bone density.

7 Oct 2011

Affymetrix commercializes 18 new array designs for whole-transcriptome analysis

Affymetrix, Inc. today announced commercialization of 18 new array designs for whole-transcriptome analysis of model and applied research organisms that will allow scientists to obtain a more complete gene expression view than traditional 3' biased arrays.

7 Oct 2011

New WPI smart-phone app can measure heart rhythm, respiration and pulse rate

An iPhone app that measures the user's heart rate is not only a popular feature with consumers, but it sparked an idea for a Worcester Polytechnic Institute (WPI) researcher who is now turning smart phones, and eventually tablet devices, into sophisticated medical monitors able to capture and transmit vital physiological data.

7 Oct 2011

Creabilis receives $20 million in Series B funding

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.

4 Oct 2011

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

3 Oct 2011

GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine.

3 Oct 2011

BIO: Advanced biofuels can be commercialized rapidly for military use

Advanced biofuels can be commercialized rapidly for military use, on military timelines, with adequate support and coordination of efforts by the U.S. Departments of Agriculture, Defense and Energy.

1 Oct 2011

DMEI dedicates new $46M research and clinical facility

Officials from the Dean McGee Eye Institute today announced the dedication of the Institute's new $46 million, five-story, 78,000-square-foot, world-class research and clinical facility.

1 Oct 2011

Nutrition experts participated in PN Safety Summit to discuss safety of PN therapy, patient care

Recent safety concerns in the preparation and delivery of parenteral nutrition, commonly referred to as intravenous nutrition, prompted leaders from several major organizations to participate in a PN Safety Summit on September 23, 2011.

From Baxter International Inc. 1 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.

From Baxter International Inc. 1 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011